Editing test page 2

TCHP (Taxotere)

back to top

TCHP: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Pertuzumab

Regimen

Study	Evidence	Comparator	Efficacy
von Minckwitz et al. 2017 (APHINITY)	Phase III	TCH	Seems to have superior invasive DFS

Preceding treatment

• Surgery

Chemotherapy

• Docetaxel (Taxotere) as follows:
  • Cycles 1 to 6: 75 mg/m² IV once on day 1
• Carboplatin (Paraplatin) as follows:
  • Cycles 1 to 6: AUC 6 (maximum dose: 900 mg) IV once on day 1
• Trastuzumab (Herceptin) as follows:
  • Cycle 1: 8 mg/kg IV once on day 1
  • Cycle 2 onwards: 6 mg/kg IV once on day 1
• Pertuzumab (Perjeta) as follows:
  • Cycle 1: 840 mg IV once on day 1
  • Cycle 2 onwards: 420 mg IV once on day 1

21-day cycle for up to 1 year of therapy (18 doses of trastuzumab & pertuzumab)

References

1. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. link to original article link to supplementary protocol contains verified protocol in supplementary protocol link to PMC article PubMed